Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Other financing activities (2023 - 2025)

Historic Other financing activities for TriSalus Life Sciences (TLSIW) over the last 3 years, with Q2 2025 value amounting to $1.0 million.

  • TriSalus Life Sciences' Other financing activities fell 6031.62% to $1.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 3999.23%. This contributed to the annual value of $2.6 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that TriSalus Life Sciences reported Other financing activities of $1.0 million as of Q2 2025, which was down 6031.62% from $520000.0 recorded in Q1 2025.
  • TriSalus Life Sciences' Other financing activities' 5-year high stood at $2.6 million during Q2 2024, with a 5-year trough of -$199633.0 in Q2 2023.
  • For the 3-year period, TriSalus Life Sciences' Other financing activities averaged around $691500.0, with its median value being $359816.5 (2023).
  • Its Other financing activities has fluctuated over the past 5 years, first surged by 139888.35% in 2024, then tumbled by 6031.62% in 2025.
  • Over the past 3 years, TriSalus Life Sciences' Other financing activities (Quarter) stood at -$199633.0 in 2023, then skyrocketed by 103.51% to $7000.0 in 2024, then skyrocketed by 14600.0% to $1.0 million in 2025.
  • Its Other financing activities was $1.0 million in Q2 2025, compared to $520000.0 in Q1 2025 and $7000.0 in Q4 2024.